Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GAPDH antisense RNA 1 (GAPDH-AS1) is a non-coding RNA transcribed from the strand opposite the GAPDH gene. It belongs to the class of long non-coding RNAs (lncRNAs), which are emerging as important regulators of gene expression and cellular function. Like other antisense lncRNAs, GAPDH-AS1 may modulate the expression or function of its sense gene (GAPDH) or participate in chromatin and RNA-level regulatory phenomena, but robust mechanistic or functional data for GAPDH-AS1 are currently lacking[5]. While the GAPDH protein is well studied and broadly implicated in cellular metabolism and gene regulation, GAPDH-AS1 itself is not widely described as a direct therapeutic target, biomarker, or drug-interacting molecule. Its main scientific interest is as a putative regulatory non-coding RNA in human cells[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on GAPDH antisense RNA 1 (GAPDH-AS1).